157 related articles for article (PubMed ID: 36915064)
1. The effect of anti-coagulation dosage on the outcome of hospitalized COVID-19 patients in Ethiopia: a multi-center retrospective cohort study.
Tessema AG; Mengiste ZM; Hundie TG; Yosef HG; Huluka DK; Seyoum AB; Abate HK; Howe RC
BMC Pulm Med; 2023 Mar; 23(1):85. PubMed ID: 36915064
[TBL] [Abstract][Full Text] [Related]
2. Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19.
Vaughn VM; Yost M; Abshire C; Flanders SA; Paje D; Grant P; Kaatz S; Kim T; Barnes GD
JAMA Netw Open; 2021 Jun; 4(6):e2111788. PubMed ID: 34115129
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic anticoagulants for people hospitalised with COVID-19.
Flumignan RL; Tinôco JDS; Pascoal PI; Areias LL; Cossi MS; Fernandes MI; Costa IK; Souza L; Matar CF; Tendal B; Trevisani VF; Atallah ÁN; Nakano LC
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013739. PubMed ID: 33502773
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O;
Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856
[TBL] [Abstract][Full Text] [Related]
5. Adoption of a National Prophylactic Anticoagulation Guideline for Hospitalized Pregnant Women With COVID-19: Retrospective Cohort Study.
Hwang YM; Piekos S; Sorensen T; Hood L; Hadlock J
JMIR Public Health Surveill; 2023 Jul; 9():e45586. PubMed ID: 37311123
[TBL] [Abstract][Full Text] [Related]
6. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
7. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
Perepu US; Chambers I; Wahab A; Ten Eyck P; Wu C; Dayal S; Sutamtewagul G; Bailey SR; Rosenstein LJ; Lentz SR
J Thromb Haemost; 2021 Sep; 19(9):2225-2234. PubMed ID: 34236768
[TBL] [Abstract][Full Text] [Related]
8. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.
Rentsch CT; Beckman JA; Tomlinson L; Gellad WF; Alcorn C; Kidwai-Khan F; Skanderson M; Brittain E; King JT; Ho YL; Eden S; Kundu S; Lann MF; Greevy RA; Ho PM; Heidenreich PA; Jacobson DA; Douglas IJ; Tate JP; Evans SJW; Atkins D; Justice AC; Freiberg MS
BMJ; 2021 Feb; 372():n311. PubMed ID: 33574135
[TBL] [Abstract][Full Text] [Related]
9. Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study.
Matli K; Chamoun N; Fares A; Zibara V; Al-Osta S; Nasrallah R; Salameh P; Mokhbat J; Ghanem G
Open Heart; 2021 Oct; 8(2):. PubMed ID: 34611018
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19.
Hoogenboom WS; Lu JQ; Musheyev B; Borg L; Janowicz R; Pamlayne S; Hou W; Duong TQ
PLoS One; 2022; 17(1):e0262811. PubMed ID: 35045130
[TBL] [Abstract][Full Text] [Related]
11. Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States.
Rentsch CT; Beckman JA; Tomlinson L; Gellad WF; Alcorn C; Kidwai-Khan F; Skanderson M; Brittain E; King JT; Ho YL; Eden S; Kundu S; Lann MF; Greevy RA; Ho PM; Heidenreich PA; Jacobson DA; Douglas IJ; Tate JP; Evans SJ; Atkins D; Justice AC; Freiberg MS
medRxiv; 2020 Dec; ():. PubMed ID: 33330896
[TBL] [Abstract][Full Text] [Related]
12. The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials.
Kow CS; Ramachandram DS; Hasan SS
J Infect Chemother; 2022 Feb; 28(2):257-265. PubMed ID: 34840039
[TBL] [Abstract][Full Text] [Related]
13. Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
Barco S; Bingisser R; Colucci G; Frenk A; Gerber B; Held U; Mach F; Mazzolai L; Righini M; Rosemann T; Sebastian T; Spescha R; Stortecky S; Windecker S; Kucher N
Trials; 2020 Sep; 21(1):770. PubMed ID: 32907635
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019.
Chang H; Rockman CB; Jacobowitz GR; Speranza G; Johnson WS; Horowitz JM; Garg K; Maldonado TS; Sadek M; Barfield ME
J Vasc Surg Venous Lymphat Disord; 2021 May; 9(3):597-604. PubMed ID: 33039545
[TBL] [Abstract][Full Text] [Related]
16. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients.
Volteas P; Drakos P; Alkadaa LN; Cleri NA; Asencio AA; Oganov A; Giannopoulos S; Saadon JR; Mikell CB; Rubano JA; Labropoulos N; Tassiopoulos AK; Mofakham S; Bannazadeh M
J Vasc Surg Venous Lymphat Disord; 2022 Sep; 10(5):1128-1136. PubMed ID: 35716998
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.
Billett HH; Reyes-Gil M; Szymanski J; Ikemura K; Stahl LR; Lo Y; Rahman S; Gonzalez-Lugo JD; Kushnir M; Barouqa M; Golestaneh L; Bellin E
Thromb Haemost; 2020 Dec; 120(12):1691-1699. PubMed ID: 33186991
[TBL] [Abstract][Full Text] [Related]
19. Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19.
Stone GW; Farkouh ME; Lala A; Tinuoye E; Dressler O; Moreno PR; Palacios IF; Goodman SG; Esper RB; Abizaid A; Varade D; Betancur JF; Ricalde A; Payro G; Castellano JM; Hung IFN; Nadkarni GN; Giustino G; Godoy LC; Feinman J; Camaj A; Bienstock SW; Furtado RHM; Granada C; Bustamante J; Peyra C; Contreras J; Owen R; Bhatt DL; Pocock SJ; Fuster V;
J Am Coll Cardiol; 2023 May; 81(18):1747-1762. PubMed ID: 36889611
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study.
Chocron R; Galand V; Cellier J; Gendron N; Pommier T; Bory O; Khider L; Trimaille A; Goudot G; Weizman O; Alsac JM; Geneste L; Schmeltz A; Panagides V; Philippe A; Marsou W; Ben Abdallah I; Deney A; El Batti S; Attou S; Juvin P; Delmotte T; Messas E; Pezel T; Planquette B; Duceau B; Gaussem P; Sutter W; Sanchez O; Waldman V; Diehl JL; Mirault T; Bonnet G; Cohen A; Smadja DM;
J Am Heart Assoc; 2021 Apr; 10(8):e018624. PubMed ID: 33550816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
